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Abstract
Although certain risk factors can identify individuals who aremost likely to develop chronic pain, few interventions to prevent chronic pain
have been identified. To facilitate the identification of preventive interventions, an IMMPACTmeeting was convened to discuss research
design considerations for clinical trials investigating the prevention of chronic pain. We present general design considerations for
prevention trials in populations that are at relatively high risk for developing chronic pain. Specific design considerations included subject
identification, timing andduration of treatment, outcomes, timingof assessment, andadjusting for risk factors in theanalyses.Weprovide
a detailed examination of 4 models of chronic pain prevention (ie, chronic postsurgical pain, postherpetic neuralgia, chronic low back
pain, and painful chemotherapy-induced peripheral neuropathy). The issues discussed can, in many instances, be extrapolated to other
chronic pain conditions. These examples were selected because they are representative models of primary and secondary prevention,
reflect persistent pain resulting from multiple insults (ie, surgery, viral infection, injury, and toxic or noxious element exposure), and are
chronically painful conditions that are treated with a range of interventions. Improvements in the design of chronic pain prevention trials
could improve assay sensitivity and thus accelerate the identification of efficacious interventions. Such interventions would have the
potential to reduce the prevalence of chronic pain in the population. Additionally, standardization of outcomes in prevention clinical trials
will facilitate meta-analyses and systematic reviews and improve detection of preventive strategies emerging from clinical trials.
Keywords: Prevention trial design, Chronic postsurgical pain, Postherpetic neuralgia, Chronic low back pain, Chemotherapy-
induced peripheral neuropathy, Risk factors
1. Introduction
Chronic pain is highly prevalent and difficult to treat.80Moreover, it
is a costly public health problem, contributing to high health care
costs and lost productivity.11,17,20,56,99 Although certain risk
factors can identify individuals who are most likely to develop
chronic pain, very few interventions to prevent chronic pain have
been identified, adopted for use in clinical practice, or approved
by regulatory agencies. Chronic pain that develops after an injury
has resolved, a toxicity or noxious element has been removed, or
an infection has resolved have all been hypothesized, at least in
part, to be mediated by nerve damage either from the insult itself
or from an increase in the excitability and responsiveness of
neurons in the spine (ie, central sensitization) due to severe acute
pain.178 If nerve damage during the initiating insult contributes to
chronic pain, minimizing that damage as early as possible will
likely decrease both acute and chronic pain. If the persistent pain
is, at least in part, caused by central sensitization, preventing or
minimizing acute pain at the time of insult may prevent the
development of chronic pain. In other instances, such as chronic
low back pain (CLBP), preventing reinjury could provide an
approach for preventing chronic or recurrent pain.
In this article, we discuss research design considerations for
clinical trials that evaluate both primary and secondary preventive
interventions that target mechanisms that putatively contribute to
Sponsorships or competing interests that may be relevant to content are disclosed
at the end of this article.
a Department of Anesthesiology, University of Rochester, Rochester, NY, USA,
b University ofWashington, Seattle,WA,USA, c University of Pennsylvania, Philadelphia,
PA, USA, d University of Florida, Gainesville, FL, USA, e Queen’s University, Kingston,
ON, Canada, f Harvard University, Boston, MS, USA, g Johns Hopkins University,
Baltimore, MD, USA, h German Diabetes Center at Heinrich Heine University,
Du¨sseldorf, Germany, i LoraGroup, LLC,RoyalOak,MD,USA, j AmericanChronic Pain
Association, Rocklin, CA, USA, k Pfizer and Duke University, Raleigh-Duram, NC, USA,
l GlaxoSmithKline, London, United Kingdom, m Eli Lilly, Indianapolis, IN, USA, n Virtuous
Pharma, Inc, Raleigh-Durham, NC, USA, o York University, Toronto, ON, Canada,
p Rigshospitalet, Copenhagen University, Denmark, q Endo Pharmaceuticals, Inc,
Malvern, PA, USA, r Teva Pharmaceuticals, NorthWales, PA, USA, s AcelRx, Redwood
City, CA, USA, t Arlington, VA, USA, u Johnson and Johnson, Titusville, NJ, USA,
v Gru¨nenthal GMbH, Aachen, Germany, w Jazz Pharmaceuticals, Palo Alto, CA, USA
*Corresponding author. Address: Department of Anesthesiology, University of
Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Box 604,
Rochester, NY 14642, USA. Tel.:11 585 276-5661; fax:11 585 244-7271. E-mail
address: jennifer_gewandter@urmc.rochester.edu (J. S. Gewandter).
Supplemental digital content is available for this article. Direct URL citations appear
in the printed text and are provided in the HTML and PDF versions of this article on
the journal’s Web site (www.painjournalonline.com).
Published in Pain, 156(7), 1184-1197
the development of chronic pain. We focus on research design
issues that can be applied to prevention trials for any chronic pain
condition in which a patient population at high risk for developing
chronic pain can be identified. We have selected 4 models of
chronic pain prevention to discuss in detail: chronic postsurgical
pain (CPSP), postherpetic neuralgia (PHN), CLBP, and
chemotherapy-induced peripheral neuropathy (CIPN). Because
estimates of pain prevalence vary greatly depending on how the
data are collected, it is difficult to determine which pain conditions
have the greatest personal and public health impact. Thus, these 4
examples were chosen because they (1) represent models that
could be amenable to primary or secondary prevention; (2) are
conditions that are treated with a range of modalities including
pharmacological, invasive, and nonpharmacological/noninvasive
interventions; and (3) represent pain induced bymultiple etiologies.
Specifically, we chose models of surgical trauma, viral infection,
injury, and a toxicant, because these models are most commonly
discussed in the context of preventing chronic pain. This article is
not a systematic review of all published chronic pain prevention
studies in these 4 fields, andwedo not comment on efficacy of any
given preventive treatment based on single studies.
2. Methods
An Initiative on Methods, Measurement, and Pain Assessment in
Clinical Trials (IMMPACT) meeting, including a diverse group of
participants from universities, government agencies, industry,
and a patient advocacy group, with 25 representatives from the
United States, 2 from Canada, and 4 from Europe, was held to
discuss research design considerations for chronic pain pre-
vention trials. Participants were selected to represent a broad
range of relevant topics, areas of expertise, and disciplines,
whereas the number of participants was limited to promote
productive and efficient discussion.
To facilitate discussion, background lectures were presented
that examined (1) neurobiological aspects of preventing acute
and chronic pain (C.J.W.); (2) risk factors for the development of
chronic pain, including genetic predisposition (R.B.F.); (3) re-
search design considerations for clinical trials of perioperative
analgesic medications to optimize acute postoperative pain
management and recovery (S.N.R.); (4)CPSP (I.G.); (5) PHN (R.H.D.);
(6) painful diabetic peripheral neuropathy (DNP) (D.Z.); (7) HIV and
chemotherapy-associated peripheral neuropathies (M.J.P.); (8)
complex regional pain syndrome type 1 (A.L.O.); (9) chronic
neuropathic low back pain (LBP) (J.D.M.); (10) chronic musculoskel-
etal LBP (J.P.R.); and (11) critical methodologic aspects of clinical
trials to prevent chronic pain (J.T.F.).
To supplement the background presentations, a review was
performed for each of the prevention models discussed here to
identify any recent randomized clinical trials (RCTs) with relevant
prevention design features that could be described as examples of
the recommendations that were formulated through the meeting
and subsequent discussions. PubMed was searched for articles
published between June 2009 and December 2014 using the
search strategies outlined in Appendix 1 (available online as
Supplemental Digital Content at http://links.lww.com/PAIN/A78).
Ideally, recommendations for clinical trial designs should be
based on systematic studies; however, because relatively few
RCTs investigating preventive interventions for chronic pain have
been conducted (eg, see Chaparro et al.30 and Han et al.67),
information that would make it possible to attempt to attribute
falsely negative trial results to methodological issues is lacking.
The design recommendations presented in this article are based
primarily on the existing literature along with the experience and
expertise of the authors, the background presentations, the
discussions that subsequently occurred during the meeting,
circulation of a draft manuscript to all authors, and iterative revision
of the draft manuscript until approval of all authors for submission
for publication was achieved. We focus on design considerations
that are particularly relevant toprevention trials. Previous IMMPACT
recommendations as well as the CONSORT statement and
comprehensive text books are available for guidance on more
general methodological issues of clinical trials (eg, randomization
procedures, choice of active vs inactive placebo).49,62,144,148
Figure 1 presents a general research design schema for chronic
pain prevention trials that provides a framework for many of the
specific considerations discussed below. We believe that imple-
mentation of these recommendations in future chronic pain
prevention trials would expedite the development of effective
prevention strategies and facilitate the preparation of more
informative systematic reviews and meta-analyses.
3. General considerations
3.1. Acute pain severity
One prominent hypothesis regarding mechanisms underlying the
development of chronic pain is that nociceptive processes, which
also cause acute pain, can cause peripheral or central
sensitization, leading to the initiation and maintenance of chronic
pain.89,109,179 Thus, one investigational approach has been
aimed at reducing acute pain during or shortly after an inciting
painful insult to reduce both acute pain and the potential
development of chronic pain.5,30 Monitoring acute pain intensity
allows one to test the hypothesis that the effect of treatment on
preventing chronic pain is mediated by its effect on acute pain.
For example, if the preventive analgesia does not decrease either
acute pain or chronic pain, further efforts to decrease acute pain
with other agents or different dosages of the same agent as
a method to prevent chronic pain would be warranted. If acute
pain severity is lower in the treated group than in the placebo
group, but no difference in chronic pain is found between groups,
decreasing acute pain may not be sufficient to prevent chronic
pain, a possibility that has been discussed by Katz and Seltzer.90
Alternatively, it is possible that the threshold of acute pain that
triggers central sensitization is even lower than the level
experienced by the treated group. When deciding whether to
further pursue preventive treatments that target acute pain levels,
investigators should consider the degree to which the acute pain
Figure 1. General chronic pain prevention design schema. Insult models
include surgery, disease (eg, herpes zoster), injury (eg, acute low back injury),
and toxic exposure (eg, chemotherapy).
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was decreased in the treatment group and whether a larger
decrease in acute pain to reach a possibly lower acute pain
threshold is a realistic goal. For trials that use prevalence of any
chronic pain as the primary outcome, an acute pain severity
measure that assesses a similar type of pain as in the chronic pain
outcome (eg, burning pain, pain on movement) should be used.
3.2. Outcome measures
Previous IMMPACT recommendations suggested including pain
intensity and physical and emotional functioning as core outcome
domains in chronic pain trials.161 Our recommendations empha-
size pain outcomes, including presence and severity, to illustrate
variousmethodological issues in the prevention setting. However,
these considerations are also generally applicable to other
outcomes that can be important to include in prevention trials,
including physical and emotional functioning and sleep, which we
also discuss when their assessment is particularly important.
When assessing pain severity, it is important to consider the time
frame (eg, a single time point after randomization or a combination
ofmultiple assessments). Presence outcomes include any pain vs
no pain or pain above or below a “clinically meaningful” or
moderate pain intensity level (eg, average pain intensity of 3 of 10
or greater). Although an analysis based on “clinically meaningful”
pain levels may have a higher impact from a clinical and public
health perspective, it may also have less power because the
incidence of moderate to severe pain will be lower than the
incidence of any pain. Furthermore, it may be difficult to identify
clinically meaningful levels of pain for the different chronic pain
conditions given that there has been little systematic examination
of patient-reported assessments of the long-term impact of
different levels of pain. Future studies should investigate patient
opinions regarding the minimal pain intensity and duration that
would be considered to be clinically meaningful in relation to the
probability of developing such chronic pain as well as risks and
costs of the potential preventive treatment (eg, what level and
nature of side effects would the patient be willing to tolerate for an
intervention that reduced the probability of a certain intensity of
pain in the future by a specified amount or period). Better
understanding of how to define the minimal threshold of chronic
pain that would be considered clinically meaningful will allow
researchers to more accurately determine the necessary sample
sizes for RCTs of preventive analgesic treatments. It is important
to note that such clinically meaningful differences should only be
used to define responders at the individual level and should not be
extrapolated to a requiredminimumdifference between groups in
pain intensity.47 Issues regarding outcome measurement and
timing in specific prevention models are discussed further below.
Postrandomization initiation of nonstudy pain medications can
complicate the interpretation of pain severity ratings. Initiation of
such pain medications is likely to be more common in prevention
trials than in treatment trials inwhich patients have been in pain for
several months or more and often are already taking pain
medications at stable dosages. Because prevention trials start
before or soon after pain onset, it is generally not possible to
require that patients use only those nonstudy pain medications
they were taking regularly before the initiation of the trial.
Therefore, innovative ways to manage postrandomization initia-
tion of nonstudy pain medications in the analyses are especially
important in prevention trials. As a potential solution to this
problem, the US Food and Drug Administration (FDA)165 recently
recommended including an outcome that would jointly assess
pain and rescue medication in analgesic trials. For example,
a responder analysis could be conducted in which participants
are considered responders if they report chronic pain less than
a prespecified value and take less than a prespecified amount of
rescue medication. The reliability and responsiveness of such
a composite outcome measure has yet to be established, and
therefore this approach cannot be suggested for primary
outcome measures. However, considering that there is no
existing evidence-based solution for this problem and that these
types of measures have face validity, we recommend that
investigators consider including some type of composite mea-
sure as a secondary outcome. The inclusion of such measures in
future trials will provide data to examine the reliability, re-
sponsiveness, and validity of such approaches. Another option
for prevention trials is an analysis comparing treatment groups
with respect to the presence or absence of pain of any level of
intensity at a prespecified extended postinsult time point (ie, at
time point when the pain is considered to be chronic). This
analysis would likely not be complicated by the use of rescue or
concomitant analgesic medication because it is rare that chronic
pain is completely eliminated by medication.
3.3. Challenges of evaluating assay sensitivity
One challenge of conducting chronic pain prevention studies is
that very few, if any, hypothesized interventions have shown
replicated evidence of efficacy; therefore, active comparators are
not readily available to assess the assay sensitivity of particular
outcome measures or trial designs. Once an efficacious pre-
ventive intervention is identified for a condition, the sensitivity of
the outcomes proposed in this review can more easily be
evaluated. Another challenge occurs when pain existing before
the insult cannot easily be distinguished from the pain sub-
sequently caused by the insult. For example, patients who have
burning pain in the feet from DPN are likely to find it impossible to
distinguish this pain from burning pain in the feet from CIPN.
Additionally, patients undergoing surgery for back pain may not
be able to distinguish between chronic pain caused by the
surgery and residual unresolved back pain. In these instances, it
may be advantageous to exclude such patients from prevention
studies. In contrast, patients with burning pain in the feet from
DPN can probably distinguish their DPN pain from new-onset
thoracic PHN pain. In such cases, patients with existing pain can
be included in the trials, but existing chronic pain should be
examined in the analyses in a similar manner to risk factors
described in Section 3.4.
3.4. Prespecified adjustment or stratification for risk factors
Adjustment for a limited number of well-established risk factors
for the development of chronic pain could increase the ability to
detect a preventive effect.85,165 To control type I error, any
covariate adjustment made in the primary analysis or secondary
analyses should be specified before the treatment assignments
are revealed. Data from such prespecified analyses could also be
used as further evidence to address the validity of the proposed
risk factors. However, it is important to note that cohorts
participating in a clinical trial may be quite different from the
target population, and therefore associations found using clinical
trial data may not necessarily reflect the associations that exist in
the population. Furthermore, including interactions between
treatment and potential risk factors for the development of
chronic pain can identify possible subgroups for which a pre-
ventive intervention is more likely to be efficacious. Such findings
would generally be considered to be hypothesis generating,
unless incorporated in the primary analysis through preplanned
Published in Pain, 156(7), 1184-1197
adjustment for multiplicity. Researchers should also consider
using well-established risk factors as stratification variables in
randomization plans.
A potential alternative to adjustment for chronic pain risk
factors is to consider risk factors in the study entry criteria to
increase the incidence of chronic pain in the sample population.
This is a common practice in PHN prevention trials that often
include only patients with herpes zoster (HZ) aged above 50
years. Chemotherapy-induced peripheral neuropathy prevention
trials always enroll patients receiving chemotherapy with the
highest risk of CIPN, including taxanes, platinum agents, and
vinca alkaloids. In other conditions inwhich risk factors for chronic
pain have less evidential support, this may not be appropriate.
However, greater acute pain intensity (ie, severity) has frequently
been found to increase the risk of chronic pain and should
therefore be considered as a possible inclusion criterion or
covariate in secondary prevention trials of chronic pain. The
extent to which more restrictive eligibility criteria would hinder
recruitment rates should be considered before their implementa-
tion. Furthermore, such eligibility criteria would decrease the
generalizability of the findings to only patients who are identified
as at high risk for the development of chronic pain. However,
a trial that includes only patients considered to be at high risk will
likely require a smaller sample size.
In general, the number of adjustments made in the primary
analysis should be limited because covariates that are not
predictive of the outcome can decrease power, especially for
studieswith a small number of participants. It is also important to
note that it is generally not appropriate to adjust for a risk factor
that is measured postbaseline because it could be altered by the
experimental treatment. For example, adjusting for cumulative
dosage of chemotherapy in a trial of a preventive treatment for
CIPN might produce misleading results because the treatment
may have an effect on both the cumulative dosage of
chemotherapy and the development of CIPN. An exception to
this occurs when one is interested in testing specific hypotheses
concerning factors that maymediate the effect of a treatment on
prevention of pain. For example, structural equation mod-
els116,134 can be used to examine whether the effect of
a treatment on prevention of chronic pain is mediated through
its effect on acute pain. It is beyond the scope of this work to
perform a systematic review of the literature to identify and
evaluate the level of evidence for risk factors for each of the 4
chronic pain models discussed here. However, investigators
should review the literature when planning chronic pain
prevention trials to identify evidence-based risk factors that
should be considered when developing the study design and
analyses.
3.5. Genetic factors
Genetic factors contribute significantly to the variability in both
pain and analgesic responses; therefore, consideration of
genetics is important in the design and conduct of chronic pain
prevention trials. Multiple candidate genes have been associated
with laboratory measures of pain sensitivity and with clinical
pain.38,39 In particular, 3 genes have shown consistent associ-
ations with both experimental and clinical pain responses: the
catechol-O-methyltransferase gene (COMT), the mu-opioid re-
ceptor gene (OPRM1), and the GTP-cyclohydrolase gene
(GCH1).114 Regarding COMT, polymorphisms and haplotypes
have been associated with laboratory pain sensitivity and acute
and chronic clinical pain,13,40 including long-term outcomes after
back surgery.142 Similarly, the A118G polymorphism of OPRM1
has been associated with experimental pain sensitivity and with
clinical pain,53,70,122 including long-term outcomes of acute back
pain.123 Finally, GCH1 genotypes have been associated with
experimental and clinical pain responses across several
cohorts,15,28,158,159 and GCH1 genotypes have predicted out-
comes from lumbar spine surgery.95,159 Genetic factors can also
impact postoperative analgesic responses, which may impact
CPSP because acute pain severity is among the strongest
predictors of CPSP. In addition tomultiple genes that impact drug
metabolism,143 COMT29,36 and OPRM179,151 have been asso-
ciated with postoperative opioid analgesic requirements.
Importantly, these genes can interact with each other and with
nongenetic factors to influence pain responses and analgesic
requirements. For example, previous studies have reported that
COMT, OPRM1, and GCH1 show sex-specific associations with
pain responses.14,15,123 In addition,COMT haplotypes have been
shown to interact with psychological functioning (ie, pain
catastrophizing) to predict both experimental and clinical
shoulder pain outcomes.58,60 Research has shown that OPRM1
and COMT exerted combined effects on the total dosage of
morphine consumed by patients with chronic cancer-related
pain.137 Specifically, individuals who were homozygous for both
the Val allele of COMT Val158Met polymorphism and the 118A
allele of OPRM1 required significantly lower morphine dosages
compared with all other groups. Genetic factors can also directly
impact responses to pharmacologic interventions; therefore,
genetic variables should be considered for incorporation into trials
designed to reduce the risk of chronic pain as potential covariates
to increase power or allow examination of differential treatment
response in patient subgroups.
Although some trials may be developed to address genetic
factors, many trials may not be designed or have sufficient power
to test genetic hypotheses. In these cases, collection and storage
of biological samples for future genotyping would be an ideal
approach. This practice could create a rich resource for future
analyses designed to identify genetic influences on the de-
velopment of chronic postoperative pain and its prevention. The
added logistical and administrative burden is relatively small in
proportion to the potential scientific and translational value that
such information could provide.
4. Design considerations in the context of 4
illustrative prevention models
4.1. Chronic postsurgical pain
Several definitions of CPSP have been proposed, including
a recent proposal based on research findings and current
knowledge of pathophysiologic mechanisms.171 Chronic post-
surgical pain occurs after the damaged tissue has healed, and
thus a large component is believed to be neuropathic.69 Although
CPSP is generally believed to be a result of surgery-induced nerve
damage, the exact mechanisms and also whether the mecha-
nisms are similar between different surgery types are unknown.
Potential causes include peripheral and central sensitiza-
tion.21,104,109,178,179 It is important to note that in specific
circumstances, pain is likely not neuropathic. For example,
postherniotomy pain could be due to irritation from themesh, and
once that mesh is removed, the pain could subside. Chronic
postsurgical pain has been considered an excellent model to
study chronic pain prevention because the exact timing of the
injury is known, allowing for primary prevention. One potential
drawback of CPSP models is that surgery is often used to treat
painful conditions, and it can be difficult to avoid confounding
from presurgery pain in the outcome analyses. Chronic
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postsurgical pain models with little to no presurgical pain (eg,
thoracotomy) can be used to prevent confounding.
Preventive efficacy of a compound for CPSP should first be
studied in surgical pain models with higher incidences of CPSP
(ie, 20%-60%), such as mastectomy, thoracotomy, amputation,
and inguinal hernia repair,21,69 to decrease necessary sample
sizes. Pain prevention studies using similar pharmaceutical
agents in different postoperative models have yielded inconsis-
tent results,27,119,120,149 suggesting that different mechanisms
may be involved compared with other persistent postoperative
pain states. This inconsistency could be due to variable efficacy of
similar drugs in different models, or it could represent false-
negative results due to low power or other methodological issues.
Therefore, any interventions found to be efficacious in surgeries
with high rates of CPSP should be tested in other models before
being used clinically in other surgical settings.88,98
4.1.1. Treatment timing
Primary chronic pain prevention, which is treatment initiated
before exposure to the pain causing agent or event, is ideal.
Primary preventive treatments for CPSP should generally be
initiated so that treatments are ideally at their effective dosage
before the surgery begins. This may require days or even weeks
of titration to target dosage with medications such as
duloxetine, gabapentin, or pregabalin. Many prevention
studies for CPSP have initiated gabapentin and other oral
medications between 1 hour and 1 day before sur-
gery.3,12,24,25,27,33,51,52,57,66,94,96,97,100,107,115,130,132,146,147,164
One study initiated treatment with an antidepressant 2 to 3
weeks before coronary artery bypass surgery; however, chronic
pain was only assessed as part of a composite quality of life
measure.31
Acute postsurgical pain includes all pain that occurs before
healing of the tissue damage from the surgery.105 When feasible
and reasonable, preventive interventions for CPSP should
generally be continued as long as the tissue damage from the
surgery is present and for the entire duration of acute post-
operative pain. This type of pain, however, can last for months for
certain surgeries (eg, thoracotomy or total knee replacement).
Depending on the type of investigational intervention, it may not
be feasible or sensible to extend the treatment for the full duration
of the acute pain period. For example, an intravenous (i.v.) or
subcutaneous (s.c.) analgesic that is given throughout the
surgery and/or postoperative stay will likely not cover the entire
duration of the acute pain period but may still be effective at
reducing chronic pain. Several prevention trials have investigated
i.v. or s.c. medications administered before, during, and between
1 and 4 days after surgery.34,42,65,71,157,170 An oral analgesic,
however, can be administered throughout the entire acute pain
period, in both clinical trials and clinical practice, thus continuing
such an intervention throughout the entire acute pain recovery
period should be considered. This recommendation is based on
the hypothesis that chronic pain is caused, at least in part, by
pathophysiologic mechanisms associated with acute pain. If
another mechanism (eg, nerve injury) is responsible for the
development of CPSP, analgesic treatment for the entire duration
of tissue damagemay not be necessary, especially in instances in
which continued treatment with the experimental intervention is
associated with unacceptable adverse events or high cost. We
suggest that the period in which postsurgical pain is considered
acute should be based on natural history data specific to each
surgery model or, in the absence of epidemiological data, the
clinical expertise of the investigator. Several clinical trials have
extended the investigational treatment between 5 and 14 days
after surgery.3,27,51,52,66,94,107,119,132
4.1.2. Outcome measures and assessment timing
Whether using a continuous pain intensity measure (eg, numeric
rating scale (NRS) or visual analog scale) or a binary any pain vs no
painmeasure, “pain intensity uponmovement” should be included
in CPSP trials as a component of the acute and chronic pain
assessments.92 Various trials have assessed CPSP using
relatively non-specific movement descriptions, for instance “while
coughing,”124,164 “during daily activities,”12 “while moving,”87,169
or during a defined movement protocol.3 Procedure-specific
validated assessments of pain-related functional consequences,
such as those described for hernia surgery,54 thoracic surgery,139
and breast4 surgery, have been developed. Inclusion of these
measures in future studies could help characterize their respon-
sivity to change, which has yet to be investigated. Pain measures
that assess both neuropathic and nonneuropathic pain qualities,
such as the Short-formMcGill Pain Questionnaire-2,50 or that only
assess neuropathic pain qualities, such as the Neuropathic Pain
Symptom Inventory,22 can alsobe included to assess thenature of
the CPSP.105 If the pain qualities are different before and after
surgery, the pain canmore confidently be attributed to the surgery.
Multiple studies have included neuropathic pain measures as
CPSP study outcomes.12,19,27,33,51,65,66,77,87,107
The primary assessment time for CPSP should be assessed at
a point after surgery when the tissue damage would be expected
to have healed, but not so long that the prevalence of the CPSP is
too low to detect a difference between groups with a reasonable
number of study subjects. Early CPSP assessments should be
administered shortly after the surgical tissue damage is expected
to heal. To improve opportunities for future meta-analyses, all
CPSP trials should also include 3, 6, and 12month assessments,
whenever possible. Acute pain outcomes (eg, 24-48 hours after
surgery) and use of nonstudy analgesic treatments should be
collected although the primary aim of the study is to investigate
the prevention of CPSP. These data can contribute to our
understanding of whether acute pain predicts chronic pain and
whether different acute factors contribute to the transition from
acute to chronic pain (ie, 24-72 hours to 3months) than those that
contribute to the persistence of chronic pain (ie, 6 months to
1 year), which has been investigated in previous studies.86,145
4.2. Postherpetic neuralgia
Postherpetic neuralgia is persistent pain that occurs after HZ
infection (ie, shingles), which may be caused by central
sensitization from acute HZ pain.141 Herpes zoster causes
a unilateral, dermatomal, usually painful, vesicular rash.45 The 3
best-established risk factors for PHN after HZ infection are
advanced age (.50 years), greater HZ rash severity, and more
severe pain during the HZ infection.46 Approximately 20% of
patients who have HZ and are aged above 50 years develop PHN
even with antiviral therapy, which is the only preventive treatment
for PHN that has shown replicated efficacy.18,44,82,162,163,177 We
recommend that investigators include only patients aged above
50 years in these studies to maximize power. Furthermore, they
should consider using a minimum acute pain score (eg, greater
than 3 on a 0-10 NRS) at the time of enrollment to further increase
the number of patients who will develop PHN.32,84,110,117,174
A vaccine is available that decreases the risk of HZ infection
and in so doing decreases the risk of developing PHN. However,
the vaccine did not decrease the risk of developing PHN in
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patients who developed HZ after being vaccinated126 and is
therefore less directly relevant to the prevention of chronic pain.
4.2.1. Treatment timing
Before the HZ infection, it is difficult to predict which individuals
will develop PHN; therefore, only secondary prevention (ie,
prevention of transition to chronic pain after exposure to a pain
causing agent or event) is possible without recruiting an extremely
large sample of participants. Ideally, preventive treatment should
be started as soon as possible after the initial insult, in this case,
the HZ infection and rash onset. Patient recruitment is often
a limiting factor in how early in the course of HZ progression the
preventive treatment can be initiated. Patients typically do not visit
their doctor until after the rash appears, and HZ is usually treated
by primary care physicians. Thus, close collaborations with
primary care physicians are encouraged.125 Investigators should
also identify a maximum duration of HZ rash for study eligibility.
Cutoffs of 3,173,177 6,43 or 7 days83,129,167 after rash onset have
been used in previous trials. Because antiviral treatment
decreases HZ severity and the duration of PHN,162 all subjects
in PHNprevention trials should be treatedwith an antiviral agent in
addition to either the investigational treatment or placebo.
The natural history of HZ infection and progression of PHN has
been studied in detail.6,45 Pain existing up to 30 days after HZ
rash onset is considered acute, and preventive treatment
throughout this period in clinical trials is encouraged. This could
include oral medications taken daily for up to 30 days (but
probably for not less than 2 weeks) and single or intermittent
treatments whose effects are believed to persist beyond their
administration (eg, nerve blocks of various types). Investigation of
treatments that target the infection (eg, novel antiviral therapies or
treatments that enhance immune function) is an exception to
these considerations. These treatments would likely only be
beneficial while the HZ infection is active, although their effects on
reducing nerve damage could have long-term benefits. Seven
days of antiviral treatment was shown to decrease the duration of
PHN in a study in which the median time to last positive viral
culture was 2 days in the placebo group; this suggests that 7 days
likely covers the period of active infection in the majority of
patients and would be a reasonable treatment time for
interventions that target the acute infection.162
4.2.2. Outcome measures and assessment timing
The frequency with which PHN eventually resolves depends on
how long after rash onset the HZ-associated pain has persisted.
The rate of pain resolution in patients whose pain has persisted at
least 4 months after rash onset seems to be less than the rate of
resolution in patients whose pain has lasted less than 4 months;
thus, it has been suggested that PHN can be defined as pain
persisting at least 4 months after rash onset.45 This 4-month time
point can be considered for primary analyses in PHN prevention
trials, although pain persisting for 90 days after rash onset—the
definition of PHN used in the Shingles Prevention Study of
vaccination—is also reasonable.126
Prevalence of any persisting HZ-associated pain at a prespe-
cified time point after rash onset has been used to assess efficacy
of PHN prevention treatments.23,83,106,129,167 Whether using
a continuous pain intensity measure or a binary pain prevalence
outcomemeasure, participants in PHN prevention studies should
be instructed to consider only the pain that is located in the area
that their HZ rash had been present. If overall pain intensity is
assessed using an NRS or other rating scale, participants should
also be asked separately about pain in response to nonpainful
stimuli, especially from light touch (ie, allodynia).
4.3. Chronic low back pain
Chronic low back pain was recently defined by the NIH task force
on research standards for CLBP as pain occurring between the
lower posterior region of the rib cage and the horizontal gluteal
fold that has lasted every day for at least 3 months and occurred
on at least half the days for a minimum of 6 months.37 A recent
global evaluation of disease burden found that LBP was the
greatest contributor to disability of the 291 diseases studied.78
The strongest predictor of developing CLBP is experiencing an
acute LBP episode. Studies suggest that only 25% to 58% of
patients with acute LBP will fully recover within 12 months of the
original episode, with the remaining patients experiencing
recurring episodes of acute pain or persistent chronic
pain.35,75,93,131 Predicting which patients with acute back pain
will develop chronic pain is challenging, which canmake it difficult
to identify patients to enroll in a prevention trial.
The STarT Back Tool (SBT) combines 9 repeatedly identified risk
factors (ie, leg pain, comorbid pain, 2 disability items, bother-
someness, catastrophizing, fear, anxiety, and depression). Con-
sidering that multiple studies demonstrate the ability of the SBT to
predict chronic pain or disability,16,76,168 investigators could
consider including this as a covariate in the primary analyses of
prevention trials. This practice would also better characterize the
prognostic value of the SBT for different populations of patients
with acute back pain. The SBT was shown to have relatively high
specificity when predicting poor outcomes in 2 studies76,168;
therefore, investigators could consider using the SBT to identify
patients likely to experience CLBP for enrollment in prevention
trials. However, because of the relatively low sensitivity of the SBT,
even in the studies demonstrating its prognostic value, many
patients who would be excluded from a clinical trial using this
measure would develop CLBP, potentially limiting the generaliz-
ability of the trial’s results. It is important to note, however, that the
optimal balance between sensitivity and specificity of a screening
tool depends on the purpose of the screening.118
Optimal participants for a CLBP prevention trial would be
patients who are experiencing their first LBP episode; however,
these patients are relatively rare in the adult population and such
an inclusion criterion could be expected to increase the
enrollment time and cost of a trial. To minimize the number of
patients included in a prevention trial who already frequently
experience recurrent LBP episodes, investigators could consider
limiting recruitment to patients who have not visited a clinician for
LBP or experienced a recurrence of back pain for some period
before the current episode, for example, 6 months or 1 year.168
The pathophysiological mechanisms of nonspecific LBP are
largely unknown. Like the other chronic pain conditions
discussed here, severe acute LBP has been shown to predict
CLBP. Thus, controlling acute LBP initially could potentially
prevent chronic back pain by decreasing central sensitization or
other peripheral or central mechanisms. However, evidence
suggests that CLBP also has a large psychosocial component.
Furthermore, physical therapy and spinal manipulation are often
used to promote healing of acute LBP in clinical practice. As
a result, the types of interventions used to prevent CLBP often
include nonpharmacologic treatments. The type and mechanism
of an intervention intended to prevent the development of CLBP
in patients with acute back pain must be carefully considered
when applying these recommendations to trials designed to test
these interventions.
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4.3.1. Treatment timing
The CLBP study designs proposed are trials of secondary
prevention, and thus the acceptable length of time after initiation
of the acute pain episode needs to be considered. Assuming that
decreasing acute LBP truly prevents the transition to CLBP,
enrolling participants as close as possible to the start of their pain
episode would be optimal. Data from a prospective study by Croft
et al.35 suggest that the earlier patients present at the clinic for
treatment, the more likely they are to recover by 3 and 6 months.
Previous prospective studies have recruited LBP patients experi-
encing an LBP episode of less than 2,72 3,55,152 and 6 weeks.175
The exact time point at which an acute back pain injury begins
and is resolved is difficult to identify and likely differs greatly
among patients. Research suggests that few patients who still
experience LBP at 3 months after the initial episode will fully
recover,26,35,81,93,131 suggesting that by 3months acute LBP has
likely become chronic, which is consistent with the NIH task force
definition of CLBP.37 Thus, administering preventive treatments
for 3months after enrollment would likely be sufficient to cover the
period of most patients’ acute injury pain. A full 3-month
treatment may not be necessary, however, for interventions with
lasting effects such as self-hypnosis or relaxation training. The
duration of the preventive interventions should be based on
previous studies of similar interventions to avoid unnecessary
burden on patients and reduce study costs.
4.3.2. Outcome measures and assessment timing
The NIH task force recommends that all research studies
involving participants with LBP include a minimum data set with
the domains of physical function, depression, sleep disturbance,
and catastrophizing.37 The presentation of CLBP is variable;
patients can experience a consistent level of pain or recurring
episodes of severe pain interspersed with periods of moderate
pain intensity or even no symptoms.93 This variable pattern can
make it difficult to capture the pain experience for all patients in
a single primary end point if the intervention is targeted at
preventing both steady chronic and episodic pain. Chronic low
back pain prevention studies have used outcomes such as pain
intensity (with various recall periods) at a prespecified time
point.2,59,61,108,156,160,172 Although these outcomes can provide
valuable information, if an individual experiences variable pain, the
outcome will be very different depending on whether the
prespecified assessment point falls during a period of high or
low pain.118 Similarly, a time to recovery outcome (used in Ref.
68), may not reflect severity for patients with episodic pain. A
recent study by Williams et al.175 used a time to recovery of at
least 7 days, which could increase the validity of this type of
outcome measure for episodic patients whose pain fluctuates
frequently. The number of LBP recurrences or painful months in
a prespecified period (used in Refs. 41,102) will more accurately
represent episodic or variable pain. These outcomes, however,
may minimize the pain experience of an individual who
consistently experiences moderate to severe pain. By monitoring
back pain on a daily basis, from baseline until 6 months, patients
couldbe stratified into 2 groups: thosewhomeet theNIH task force
definition of CLBP (ie, pain every day for 3 months or for half of the
days for 6 months) and those who do not. This type of outcome
measure would include both chronic and frequent episodic pain
but would have limited power because of its dichotomous nature
and the fact that it does not account for pain severity. The area
under the curve of periodic pain intensity assessments over
a prespecified period would represent pain severity in individuals
who experience different pain patterns and would be a continuous
outcome variable, thus potentially increasing the power of the
analysis. This type of outcome variable was used in the Shingles
Prevention Study to characterize the overall severity and persis-
tence of HZ pain.126 The frequency of assessment for an area
under the curve outcome should be determined based on
consideration of patient burden and reasonable recall periods.
Suni et al.156 requiredpatients to keepaweeklydiary for 12months,
suggesting that frequent data collection is possible; however, the
level of diary compliance was not reported.
Investigators should consider assessing the efficacy of CLBP
preventive treatments at 3, 6, and 12 months or a period that
encompasses these time points. These time points are consistent
with the NIH task force37 definition of CLBP and with the many
epidemiologic studies that investigate persistent CLBP at
12 months. Study designs should avoid assessing the outcome
too close to the end of the preventive intervention to clearly
distinguish prevention as opposed tomanagement of symptoms.
For example, if the investigational treatment lasts for 3 months,
investigators should consider measuring the primary outcome
variable at 6 or 12 months.
4.4. Chemotherapy-induced peripheral neuropathy
Chemotherapy-inducedperipheral neuropathy is causedby various
neurotoxic chemotherapy agents (eg, platinum agents, taxanes,
vinca alkaloids, bortezomib) and includes sensory symptoms
ranging from numbness and tingling to pain and allodynia.7,10
Few clinical studies have investigated chronic CIPN, or CIPN that
persists after completion of chemotherapy. The estimated preva-
lence of chronic CIPN symptoms persisting 5 to 15 years after
completion of treatment with platinum agents ranges from 13% to
35%.64,155 One study found that 32% of patients taking vincristine
still reported neuropathic symptoms after completing vincristine
therapy, with a median duration of follow-up of 34 months;
however, no patients whowere 40months after treatment reported
neuropathic symptoms.133 Ten percent of patients who received
bortezomib developed $2 grade neuropathy that persisted for at
least 1 year.138 However, noneof these studies investigated rates of
persistent painful neuropathy, specifically. One study showed that
18% of patients receiving paclitaxel for breast cancer reported
neuropathic pain after an average of 9 years and that patients who
had experienced CIPN during chemotherapy were 3 times more
likely than those who had not developed CIPN during treatment to
report neuropathic pain after chemotherapy completion.136 How-
ever, they also found that diabetes and osteoarthritis were
associated with neuropathic pain in these cancer survivors.136
Many previous studies that examined preventive treatments for
CIPN investigated prevention of continually occurring acute
symptoms present during ongoing chemotherapy administration
and did not investigate prevention as it is classically defined (ie,
assessing outcomes after the preventive treatment is termi-
nated).73 Therefore, although these trials are different from
treatment trials because the investigational treatments are started
either before or at the same time as chemotherapywith the goal of
preventing neuropathic symptoms, we do not discuss these
designs in this article.
Eligible patients for CIPN prevention trials should be patients
scheduled to receive a neurotoxic chemotherapy (eg, platinum
agents, taxanes, vinca alkaloids, bortezomib). Patients should
also have a life expectancy that is at least 6 to 12 months longer
than their scheduled course of chemotherapy to minimize trial
attrition. Investigators should consider excluding patients who
have diabetes, HIV, or alcoholism, all of which can also cause
a peripheral neuropathy. Inclusion of these patients in trials can
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make it difficult to determine whether CIPN, a neuropathy from
another cause, or the combination ofmultiple types of neuropathy
is being investigated in the trial. Patients with diabetes have been
excluded from previous CIPN prevention studies.74,140
The specific pathophysiological mechanism of nerve damage
associated with CIPN varies depending on the neurotoxic agent,7
but acute nerve damage at the time of infusion may transition into
subacute and chronic pain, and it is possible that minimizing acute
pain may limit this transition. It is also possible, however, that
minimizing acute pain will allow patients to receive a higher
cumulative dosage of chemotherapy, which could actually lead to
increased severity of chronic painful CIPN.Other interventions could
target putative mechanisms of nerve damage, such as oxidative
stress. Clinical trial designs for CIPN prevention should be tailored
based on the treatments’ proposed mechanism(s) of action.
4.4.1. Treatment timing
Primary prevention can be studied in CIPN by initiating the
investigational treatment on or before the first day of chemotherapy.
Although achieving the target dosage of the investigational
medication before chemotherapy is administered would be ideal,
this may not be feasible if, for example, chemotherapy must be
administered very soon after a cancer diagnosis and the experimen-
talmedicationmust be titrated slowly to the effective dosage, suchas
it would likely be true of antiepileptics. In certain cases, investigators
may choose to investigate secondary prevention of painful CIPN by
enrolling patients who develop early CIPN symptoms, such as
numbness and tingling, after the initiation of chemotherapy. Doing so
would increase the percentage of participants who will develop
chronic painful CIPN in the sample, but such timing could also
attenuate the beneficial effects of a truly preventive treatment that
requires very early administration to prevent nerve damage.
It would generally be recommended that preventive treatments
should be administered throughout the duration of the insult that
causes chronic pain; however, CIPN is unique in that the pain-
inducing insult occurs at multiple intervals over a period that often
lasts for months.10,121,135,176 Whether the treatment would likely
be best given throughout the full duration of the prescribed
chemotherapy or only proximal to each chemotherapy infusion
depends on the proposed mechanism and mode of administra-
tion of the investigational drug. For example, a bolus i.v. dose of
an anti-inflammatory or other agent hypothesized to prevent
nerve damage may be best administered directly before or after
each chemotherapy infusion as was performed in multiple
studies.101,103,112,140,154 In fact, daily infusions of an investiga-
tional prophylactic CIPN treatment throughout the full course of
chemotherapy are not likely to be feasible. On the contrary, oral or
topical medications that target the nervous system—such as
antiepileptics, antidepressants, or anti-inflammatory agents that
are being used to decrease pain or augment pain inhib-
ition—would likely best be initiated before the start of chemo-
therapy and continued until the end of chemotherapy (eg, Refs.
1,74,91) or for 2 weeks to 3 months after chemotherapy
completion (eg, Refs. 8,9,63,127,128).
4.4.2. Outcome measures and assessment timing
Aswith the other preventionmodels, possible outcomemeasures
include the intensity or incidence of any pain or minimal pain
intensity associated with chemotherapy at a prespecified time
after cessation of chemotherapy. Previous studies of CIPN
prevention have focused on composite, and sometimes crude,
measures of neuropathic symptoms, such as the National
Cancer Institute–Common Toxicity Criteria (NCI-CTC) and
European Organization for Research and Treatment of
Table 1
Recommendations.
Models Treatment timing Outcome measures Assessment timing
CPSP Preoperative Presence vs absence of pain 24-48 h after surgery
Perioperative Presence vs absence of “clinically meaningful” pain 3, 6, and 12 mo
Duration of acute pain recovery (based on natural
history of recovery for each surgical model)
Pain intensity at rest Surgery-specific times based on natural history of
acute to chronic pain transitionPain intensity upon movement and specific
activities (well defined)
Pain qualities
Secondary end points: physical and emotional
functioning
PHN As soon as possible after rash onset (but # 7 d) Presence vs absence of pain in the area of the rash 3-4 mo after rash onset
Duration of acute HZ pain (# 30 d from rash onset) Presence vs absence of “clinically meaningful” pain
in the area of the rash
Pain intensity at HZ rash location
Pain qualities at HZ rash location
Secondary end points: physical and emotional
functioning
CLBP As soon as possible after an acute back pain
episode (within 3 wk)
Presence vs absence of chronic pain as defined by
the NIH Task Force37
3, 6, and 12 mo
Duration of acute pain (; 3 mo) Pain intensity
AUC of pain assessments between 3 mo and final
time point
Secondary end points: physical and emotional
functioning
Painful CIPN Prechemotherapy Presence vs absence of pain 3 and 6 mo
Duration of chemotherapy (either daily or only
proximal to chemotherapy infusions)
Presence vs absence of “clinically meaningful” pain
Secondary end points: physical and emotional
functioning
AUC, area under the curve; CIPN, chemotherapy-induced peripheral neuropathy; CLBP, chronic low back pain; CPSP, Chronic postsurgical pain; HZ, herpes zoster; PHN, postherpetic neuralgia.
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Cancer–Quality of Life Questionnaire–Chemotherapy-induced
Peripheral Neuropathy-20 (EORTC-QLQ-CIPN20) scales and
not pain specifically.73 This could explain why trials of gabapentin
and amitriptyline, which are known to be efficacious in other
neuropathic pain conditions, have failed to detect a preventive
treatment effect in CIPN91,113 andwhymany other trials have also
failed.73 A recent CIPN treatment trial by Smith et al.153 of patients
with established painful CIPN found an effect of duloxetine on
pain severity, suggesting that focusing on pain rather than
neuropathy in general could improve assay sensitivity. Of course,
the fact that the trial by Smith et al. found an effect of duloxetine
could be due to multiple factors other than the primary outcome
measure, such as the trial size and the fact that it was a treatment
trial executed solely after chemotherapy was discontinued,
eliminating the variability in neuropathic symptoms caused by
changes in chemotherapy dosing during treatment. Patients with
cancer are often treated with other agents that can cause pain,
such as antiestrogen or radiation therapy. To minimize the effect
that such treatments have on outcome measures of CIPN,
patients should be educated on the types of pain caused by
neuropathy and instructed to consider only these types of pain,
for example, only pain localized to their hands and feet.
A recent meta-analysis by Seretny et al.150 found that the
average reported prevalences of CIPN at 3 and 6 months after
termination of chemotherapywere 60% (95%confidence interval:
36%-82%) and 30% (95% confidence interval: 6.4%-54%),
respectively. However, these estimates were based on relatively
few studies (ie, 4 and 5, respectively) and are highly variable.
These data suggest that CIPN symptoms are still naturally
decreasing at 3 months after chemotherapy; therefore, 6 months
after chemotherapy would be a reasonable time point to assess
the effects of a CIPN prevention treatment, although some
patients might still have resolution of their pain after this point.
However, because these studies did not assess pain specifically,
which could have a lower prevalence at both 3 and 6months after
chemotherapy, 3 months should also be considered as an
assessment time point given that 3 months is largely considered
the minimum duration of pain that is considered to be
chronic.48,111 Previous CIPN prevention studies have assessed
neuropathy at 1month,63,127 6 weeks,166 and 3months8,9,128,140
after the cessation of chemotherapy. However, only 1 of these
trials declared the chronic CIPN outcome at the chosen time point
as the primary outcome of the study.140 An interesting secondary
analysis could also examine the “time to recovery” of neuropathic
pain after cessation of chemotherapywithin the subset of patients
who developed a prespecified level of pain. This type of outcome
was used to assess chronicity of neuropathy up to 20 months
after cessation of chemotherapy with concurrent gabapentin or
placebo treatment.113
A challenge that is unique to the CIPN prevention model is that
although everyone in the study may be prescribed the same or
one of a few chemotherapy regimens, chemotherapy is often
modified or stopped because of side effects, including neurop-
athy. The cumulative dosage of chemotherapy is highly associ-
ated with neuropathy,7,176 and thus termination of chemotherapy
after different dosages can introduce variability in neuropathy
outcomes, including pain, at any given time after cessation of
chemotherapy. Some studies have dealt with this by eliminating
participants who do not receive a prespecified minimum dosage
of chemotherapy.63,127,128,166 However, this practice could bias
the treatment effect estimate because modifications in cumula-
tive chemotherapy dosage could be affected by the investiga-
tional treatment; this issue should be carefully considered when
developing the statistical analysis plan.
5. Conclusions
Although preventing chronic pain would have substantial public
health benefits, few preventive interventions have been de-
veloped. To facilitate the design of clinical trials that would
examine the efficacy of such interventions, we have reviewed and
discussed research designs and other considerations for such
trials. We highlighted 4 models, but these considerations are
widely applicable to any pain prevention model in which patients
at relatively high risk of developing chronic pain can be identified
(Table 1 for a summary of major considerations). It must be
emphasized that many of these recommendations are not based
on systematic research, but on published chronic pain prevention
and treatment trials and the experience and expertise of the
meeting participants. The fact that the majority of the meeting
participants were from North America could be considered
a limitation. However, we believe that this is unlikely given that the
recommendations focus on trial design rather than treatment
recommendations or policy considerations. We hope that the
suggestions made in this article will stimulate interest in the
prevention of chronic pain and facilitate the development of
efficacious and safe preventive interventions.
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